Kamei, Daniel - University of California, Los Angeles

个人简介

Education B.S., University of California, Berkeley, 1995 M.S., Massachusetts Institute of Technology, 2000 Ph.D., Massachusetts Institute of Technology, 2001 Postdoctoral Training with Professors Douglas A. Lauffenburger and Bruce Tidor, Massachusetts Institute of Technology, 2001-2003 Awards and Recognitions Lockheed Martin Excellence in Teaching Award, Henry Samueli School of Engineering and Applied Science, 2016 Bill and Melinda Gates Foundation Grant for Cancer Research, 2016 UCLA Distinguished Teaching Award for Academic Senate Faculty, 2015 Early Career Award, Wallace H. Coulter Foundation, 2007-2009 Northrop Grumman Teaching Award, Henry Samueli School of Engineering and Applied Science, 2007 Professor of the Year Award, Engineering Society of UCLA (ESUC), 2007 Kimmel Scholar Award, Sidney Kimmel Foundation for Cancer Research, 2004-2006 Sloan Foundation/D.O.E. Postdoctoral Fellowship in Computational Molecular Biology, 2003-2003 NIH Interdepartmental Biotechnology Training Program Grant, 1999-2001 D.O.D. National Defense Science and Engineering Graduate Fellowship, 1995-1999

研究领域

My research program is in the area of molecular cell bioengineering, where we develop and employ quantitative design principles obtained from a cell-level context to engineer more effective molecular therapeutics. Specifically, experiment and computational modeling are combined to rationally design peptides and proteins with the goal of improving existing therapies. Instead of optimizing merely any individual step among the complex network of dynamic processes involved in cell regulation, my research takes a systems approach to analyzing cellular processes. With this quantitative analysis, design criteria for enhancing efficacy are identified and then achieved using a combination of molecular modeling and site-directed mutagenesis. One application of my research is to rationally develop therapeutic proteins with increased half-lives. Therapeutic proteins with increased half-lives should decrease the frequency of injections and allow the administration of low and potentially non-toxic concentrations of protein. Another application of my research is to improve existing cancer therapies. The overall framework used by my research group to address these problems consists of the following three parts: 1. Systems-level, engineering analysis of cellular processes 2. Molecular modeling of ligand-receptor complexes 3. Quantitative cell biology experiments to test model predictions For example, in the case of designing therapeutic proteins with longer half-lives, the systems-level, engineering analysis involves investigating cellular trafficking processes to identify design criteria in terms of molecular parameters. Molecular modeling is then performed to identify potential sites for mutations that can satisfy the design criteria. In the modeling, electrostatic, van der Waals, and hydrophobic interactions between the ligand and the receptor are calculated. Finally, quantitative binding and trafficking experiments are performed to test the predictions from the engineering analysis and the molecular modeling

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

D.J. Yoon, K.Y. Chen, A.M. Lopes, A.A. Pan, J. Shiloach, A.B. Mason, and D.T. Kamei, "Mathematical modeling of mutant transferrin-CRM107 molecular conjugates for cancer therapy," J. Theor. Biol. 416 (2017) 88-98. A.M. Lopes, K.Y. Chen, and D.T. Kamei, “A transferrin variant as the targeting ligand for polymeric nanoparticles incorporated in 3-D PLGA porous scaffolds,” Mater. Sci. Eng. C Mater. Biol. Appl. 73 (2017) 373-380. K.M. Mayle, K.R. Dern, V.K. Wong, K.Y. Chen, S. Sung, K. Ding, A.R. Rodriguez, S. Knowles, Z. Taylor, Z.H. Zhou, W.S. Grundfest, A.M. Wu, T.J. Deming, and D.T. Kamei, “Engineering A11 minibody-conjugated, polypeptide-based gold nanoshells for prostate stem cell antigen (PSCA)-targeted photothermal therapy,” J. Lab. Autom., published online on September 26, 2016. DOI: 10.1177/2211068216669710. G.L. Mosley, P. Nguyen, B.M. Wu, and D.T. Kamei, “Development of quantitative radioactive methodologies on paper to determine important lateral-flow immunoassay parameters,” Lab Chip, published online on July 1, 2016. DOI: 10.1039/c6lc00518g. K.M. Mayle, K.R. Dern, V.K. Wong, S. Sung, K. Ding, A.R. Rodriguez, Z. Taylor, Z.H. Zhou, W.S. Grundfest, T.J. Deming, and D.T. Kamei, “Polypeptide-based gold nanoshells for photothermal therapy,” J. Lab. Autom., published online on April 28, 2016. DOI: 10.1177/2211068216645292. A.R. Rodriguez, U.-J. Choe, D.T. Kamei, and T.J. Deming, “Use of methionine alkylation to prepare cationic and zwitterionic block copolypeptide vesicles,” Israel J. Chem. 56 (2016) 607-613. R.Y.T. Chiu, A.V. Thach, C.M. Wu, B.M. Wu, and D.T. Kamei, “An aqueous two-phase system for the concentration and extraction of proteins from the interface for detection using the lateral-flow immunoassay,” PLoS One 10 (2015) e0142654. B.S. Lee, A.T. Yip, A.V. Thach, A.R. Rodriguez, T.J. Deming, and D.T. Kamei. "The targeted delivery of doxorubicin with transferrin-conjugated block copolypeptide vesicles," Int. J. Pharm. 496 (2015) 903-911. D.Y. Pereira, R.Y.T. Chiu, S.C.L. Zhang, B.M. Wu, and D.T. Kamei, "Single-step, paper-based concentration and detection of a malaria biomarker," Anal Chim Acta. 882 (2015) 83-89. B. Voth, D.T. Nagasawa, P.E. Pelargos, L.K. Chung, N. Ung, Q. Gopen, S. Tenn, D.T. Kamei, and I. Yang, “Transferrin receptors and glioblastoma multiforme: Current findings and potential for treatment,” J. Clin. Neurosci. 22 (2015) 1071-1076.